Five-year Kesimpta data supports earlier use in RMS

Long-term data from the ALITHIOS open-label extension study in relapsing multiple sclerosis (RMS) shows that up to five years, patients treated earlier and continuously with Kesimpta (ofatumumab) had fewer disability worsening events and low brain volume change versus those starting on teriflunomide who later switched to the Novartis (NOVN: VX) drug.

A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified. These data will be presented at the American Academy of Neurology (AAN) Annual Meeting beginning this weekend.

"Most patients remained free from disease progression up to five years"Principal investigator Jeffrey Cohen, of the Neurological Institute at Cleveland Clinic, said: “With continuous Kesimpta treatment, key indicators of disability progression and brain volume change showed that most patients remained free from disease progression up to five years.